Physician profile
Ji Woo Lee
NPI 1720192990
$3,613.42
in general payments reported to CMS, 2019-2025
15 companies · $389 in 2025
The $389 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $578 · 2020: $101 · 2021: $330 · 2022: $947 · 2023: $925 · 2024: $344 · 2025: $389.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,658.32 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Smith+Nephew, INC. | $1,412.39 | 2019-2025 | Grafix Pl, Collagenase Santyl, Stravix |
| Kerecis Limited | $760.00 | 2022-2025 | Kerecis Omega3 Surgiclose, Kerecis Omega3 Marigen, Kerecis Surgiclose |
| Organogenesis INC. | $629.44 | 2019-2024 | Puraply |
| Integra Lifesciences Corporation | $150.00 | 2019 | |
| Bioventus LLC | $141.46 | 2022 | |
| Convatec INC. | $126.53 | 2021-2024 | |
| Paratek Pharmaceuticals, INC. | $125.01 | 2025 | Nuzyra |
| Osiris Therapeutics INC. | $100.52 | 2019 | |
| Misonix INC | $71.39 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.25 | 2021 | |
| Solventum Corporation | $18.95 | 2025 | Activ.A.C. |
| Medline Industries LP | $17.49 | 2021 | |
| Mimedx Group, INC. | $14.40 | 2025 | |
| Janssen Pharmaceuticals, INC | $11.40 | 2021 | |
| Molnlycke Health Care US, LLC | $10.19 | 2023 | Mepilex Border Ag, Mepilex, Exufiber Ag+ |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ji Woo Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.